Shire's lanadelumab found to significantly reduce HAE attacks
By Michele Maatouk
Date: Friday 16 Nov 2018
(Sharecast News) - Shire announced some positive results on Friday from a phase 3 trial evaluating the efficacy and safety of its experimental lanadelumab drug for the treatment of hereditary angioedema (HAE) - a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of swelling in various parts of the body.
The specialty biopharmaceutical company said data showed that patients treated with lanadelumab 300 mg every two weeks experienced significantly fewer HAE attacks. They were also less likely to have moderate or severe attacks or use rescue medication and were more likely to be HAE attack-free than those treated with placebo.
These results were noted during the entire 26-week treatment period.
Andreas Busch, executive vice president and head of Research and Development at Shire, said: "For those living with this chronic and unpredictable disease, it is important that they can reduce the frequency of their HAE attacks.
"Additional analysis of the HELP Study continues to support the use of lanadelumab as a preventive subcutaneous treatment option for HAE in appropriate patients 12 years of age and older."
HAE is estimated to affect about 1 in 10,000 to 1 in 50,000 people worldwide. Aside from the burden of the disease itself, patients can suffer anxiety, fatigue and depression between attacks.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN